Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland Maj Institute of Pharmacology, Polish Academy of ...

TLR7/8 have been implicated in the initiation and progression of lupus, a disease associated with defects in the clearance of apoptotic debris which can activate these receptors. However, the effects ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Ulipristal can inhibit follicular rupture when administered ... of 19-norprogesterone that functions as a selective progesterone receptor modulator (SPRM) with both agonistic and antagonistic ...

Finally, the isolated Sema domain retains the ability to competitively inhibit ligand binding and receptor dimerization, impairs activation of MET-dependent transduction pathways and reduces HGF ...

Here we show that the co-repressor nuclear-receptor-interacting protein 1 ... and Imagequant software. Progesterone was measured using the DSL3900 Active-Progesterone Coated-Tube Radioimmunoassay ...

Biological responses to progesterone are mediated by both genomic (e.g. progesterone receptor acts through specific progesterone response elements within the promoter region of target genes) and ...

However, the mechanisms underlying the induction of tumor malignancy upon inhibition of steroid hormone signaling remain poorly understood ... Our analysis of ecdysone-induced downstream targets ...

State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from ...